KCAS-blog-thumb_2024-09_LyonEmailBlog Blogs
Read article KCAS Bio to Attend a Series of Premier Global Conferences in 2024

KCAS Bio is excited to announce our participation in several key conferences throughout the world. These events present invaluable opportunities for collaboration, innovation, and the sharing of industry insights. As a leading provider of bioanalytical services, KCAS Bio is committed to engaging with thought leaders, scientists, and professionals worldwide to…

KCAS-blog-thumb_2024-09_Understanding ADA Assays Blogs
Read article Understanding Anti-Drug Antibody (ADA) Assays: The Key to Immunogenicity in Preclinical Drug Development

In both preclinical and clinical studies, evaluating immunogenicity—an immune system’s response to a foreign substance—is a critical factor. Anti-drug antibody (ADA) assays play a pivotal role in this evaluation, helping researchers and pharmaceutical companies determine how the immune system reacts to therapeutic drugs. But what exactly is immunogenicity? Simply put,…

KCAS-event-thumb_2024-09_ICCS October 4 - October 8

KCAS Bio is excited to announce our participation in the 39th International Clinical Cytometry Meeting and Course (ICCS), taking place in Seattle, Washington. This prestigious event will bring together global experts in cytometry to explore the latest advancements in clinical applications, research, and innovation. As a leader in bioanalytical services,…

KCAS-event-thumb_2024-09_BioJapan October 9 - October 11

KCAS Bio is thrilled to participate in BioJapan 2024, one of Asia’s most prominent biotechnology events, held in Yokohama, Japan. As a leader in bioanalytical and contract research services, our presence at BioJapan underscores our commitment to providing world-class solutions to the global biotech industry. This event offers an unparalleled…

KCAS-blog-thumb_2024-09_Pharmacokinetics Blogs
Read article Pharmacokinetics Unveiled: From Early Development to Method Validation and Beyond

The Role of Pharmacokinetics (PK) in Drug R&D Pharmacokinetics (PK) is defined as the study of the fate of a new therapeutic entity (NTE) after it is administered into the body of animals or humans. It involves understanding how the drug is absorbed, distributed, metabolized, and eliminated (ADME). Essentially, PK…

KCAS-webinar-thumb_2024-09_Hybrid LC-MS_MS Webinars
View webinar Hybrid LC-MS/MS Technology Becoming the New Norm in the Bioanalysis of Antibody-Drug Conjugates

As the pharmaceutical industry continues to evolve, so does the technology behind drug development. One of the most groundbreaking advancements in bioanalysis is Hybrid LC-MS/MS technology, which is rapidly becoming the new standard for analyzing Antibody Drug Conjugates (ADCs). KCAS Bio is proud to be at the forefront of this…

KCAS-event-thumb_2024-09_AusBiotech October 30 - November 1

KCAS Bio is excited to announce our attendance at AusBiotech 2024 in Melbourne, Australia. As a leader in bioanalytical services, we are committed to supporting the growth and innovation of the biotech industry. This premier event offers a unique platform to engage with industry experts, innovators, and decision-makers, all working…

KCAS-webinar-thumb_2024-09_Spectral Unmixing Webinar Webinars
View webinar Join KCAS Bio (Sept 25th) – Webinar: Spectral Unmixing Impact Comparison Across Immunophenotyping Panels and Matrices

Nassouh Mourabet is a Scientist III in the Flow Cytometry department at KCAS Bio located in Spring House, Pennsylvania. Nassouh helps clients drive the success of their flow cytometry projects. Nassouh particularly focuses on the development, optimization, validation, and data presentation of flow cytometry panels in the support of clinical…

KCAS-blog-thumb_2024-08_TargetedProtein Blogs
Read article Targeted Protein Degraders and the Role of Flow Cytometry

The exploration of Targeted Protein Degraders (TPD) as a therapeutic modality began over twenty years ago. Since then, research and development in this field have steadily advanced. Starting in 2019, rationally designed small molecule TPDs entered clinical trials. This innovative therapeutic modality utilizes the cells’ endogenous protein degradation machinery to…

KCAS-podcast-thumb_TWB-080 Podcasts
Listen to podcast Podcast (The Weekly Bioanalysis) Eps #80: “The Rapid Evolution of PCR Assays with Special Guest, Carrie Vyhlidal”

Our hosts, Dom and John, are excited to welcome special guest, Carrie Vyhlidal, to discuss the topic of the 80th episode of “The Weekly Bioanalysis” podcast – The Rapid Evolution of PCR Assays. PCR (or Polymerase Chain Reaction) is like a copying machine for DNA. Scientists have found ways to…

KCAS-blog-thumb_2024-07_The Role Dose Form Plays Blogs
Read article The Role Dose Form Plays in Preclinical Studies

Preclinical formulation analysis supports toxicity studies before and after the investigational new drug application (IND). Multiple analytical studies support drug development progression beyond the IND stage. KCAS Bio performs analytical studies for a variety of clients. How Does KCAS Bio Perform Preclinical Formulation Analysis? KCAS Bio has completed numerous studies…

KCAS-blog-webinar_2024-08_ Anti-Drug Antibodies Testing Webinars
View webinar KCAS Bio’s Webinar on Anti-Drug Antibodies Testing

In the dynamic field of biotherapeutics, understanding and managing anti-drug antibodies (ADAs) is critical for the success of drug development programs. ADAs can potentially neutralize the efficacy of biotherapeutic drugs, making it essential to have robust testing methodologies in place from the preclinical to clinical stages. KCAS Bio is excited…